{"Year":[2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020,2019,2020,2014,2015,2016,2017,2018,2019,2020,2014,2015,2016,2017,2018,2019,2020],"SDG Series":["Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) [3.b.1]","Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) [3.b.1]","Proportion of the target population with access to affordable medicines and vaccines on a sustainable basis, human papillomavirus (HPV) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) [3.b.1]"],"Value":[52,52,60,73,87,84,89,94,88,86,89,92,91,92,89,89,93,93,92,95,91,25,31,13,54,57,59,62,68,69,81,89,93,92,92,96,92]}